Literature DB >> 27956085

Effects of α-synuclein on axonal transport.

Laura A Volpicelli-Daley1.   

Abstract

Lewy bodies and Lewy neurites composed primarily of α-synuclein characterize synucleinopathies including Parkinson's disease (PD) and Dementia with Lewy Bodies (DLB). Despite decades of research on the impact of α-synuclein, little is known how abnormal inclusion made of this protein compromise neuronal function. Emerging evidence suggests that defects in axonal transport caused by aggregated α-synuclein contribute to neuronal dysfunction. These defects appear to occur well before the onset of neuronal death. Susceptible neurons in PD such as dopamine neurons with long elaborate axons may be particularly sensitive to abnormal axonal transport. Axonal transport is critical for delivery of signaling molecules to the soma responsible for neuronal differentiation and survival. In addition, axonal transport delivers degradative organelles such as endosomes and autophagosomes to lysosomes located in the soma to degrade damaged proteins and organelles. Identifying the molecular mechanisms by which axonal transport is impaired in PD and DLB may help identify novel therapeutic targets to enhance neuron survival and even possibly prevent disease progression. Here, we review the evidence that axonal transport is impaired in synucleinopathies, and describe potential mechanisms by which contribute to these defects.
Copyright © 2016. Published by Elsevier Inc.

Entities:  

Keywords:  Axonal transport; Dementia with Lewy Bodies; Lewy Bodies; Lewy neurites; Parkinson's disease; Synuclein

Mesh:

Substances:

Year:  2016        PMID: 27956085     DOI: 10.1016/j.nbd.2016.12.008

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  22 in total

1.  Alpha-synuclein: prion or prion-like?

Authors:  Rehana K Leak; Matthew P Frosch; Thomas G Beach; Glenda M Halliday
Journal:  Acta Neuropathol       Date:  2019-08-12       Impact factor: 17.088

Review 2.  The Role of α-Synuclein in Methamphetamine-Induced Neurotoxicity.

Authors:  Manqing Wu; Hang Su; Min Zhao
Journal:  Neurotox Res       Date:  2021-02-08       Impact factor: 3.911

Review 3.  α-Synuclein and Parkinsonism: Updates and Future Perspectives.

Authors:  Kaie Rosborough; Neha Patel; Lorraine V Kalia
Journal:  Curr Neurol Neurosci Rep       Date:  2017-04       Impact factor: 5.081

Review 4.  Animal models of α-synucleinopathy for Parkinson disease drug development.

Authors:  James B Koprich; Lorraine V Kalia; Jonathan M Brotchie
Journal:  Nat Rev Neurosci       Date:  2017-07-13       Impact factor: 34.870

5.  Computational modeling reveals multiple abnormalities of myocardial noradrenergic function in Lewy body diseases.

Authors:  David S Goldstein; Mark J Pekker; Graeme Eisenhofer; Yehonatan Sharabi
Journal:  JCI Insight       Date:  2019-07-23

Review 6.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-18       Impact factor: 3.575

7.  Can the lack of fibrillar form of alpha-synuclein in Lewy bodies be explained by its catalytic activity?

Authors:  Ivan A Kuznetsov; Andrey V Kuznetsov
Journal:  Math Biosci       Date:  2021-12-07       Impact factor: 2.144

Review 8.  Innate and adaptive immune responses in Parkinson's disease.

Authors:  Aubrey M Schonhoff; Gregory P Williams; Zachary D Wallen; David G Standaert; Ashley S Harms
Journal:  Prog Brain Res       Date:  2019-12-05       Impact factor: 2.453

9.  Critical appraisal of pathology transmission in the α-synuclein fibril model of Lewy body disorders.

Authors:  Negin Nouraei; Daniel M Mason; Kristin M Miner; Michael A Carcella; Tarun N Bhatia; Benjamin K Dumm; Dishaben Soni; David A Johnson; Kelvin C Luk; Rehana K Leak
Journal:  Exp Neurol       Date:  2017-10-19       Impact factor: 5.330

Review 10.  Current concepts and controversies in the pathogenesis of Parkinson's disease dementia and Dementia with Lewy Bodies.

Authors:  Rimona S Weil; Tammaryn L Lashley; Jose Bras; Anette E Schrag; Jonathan M Schott
Journal:  F1000Res       Date:  2017-08-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.